Trial · NCT00053898
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients Free From Breast Cancer | Group 1: Tamoxifen + Anastrozole Placebo | 89.1 | percentage of participants event-free | ||
| Percentage of Patients Free From Breast Cancer | Group 2: Anastrozole + Tamoxifen Placebo | 93.1 | percentage of participants event-free | ||
| Percentage of Patients Free From Invasive Breast Cancer | Group 1: Tamoxifen + Anastrozole Placebo | 93.3 | percentage of participants event-free | ||
| Percentage of Patients Free From Invasive Breast Cancer | Group 2: Anastrozole + Tamoxifen Placebo | 96.4 | percentage of participants event-free | ||
| Percentage of Patients Free From Ipsilateral Recurrence | Group 1: Tamoxifen + Anastrozole Placebo | 94.6 | percentage of participants event-free | ||
| Percentage of Patients Free From Ipsilateral Recurrence | Group 2: Anastrozole + Tamoxifen Placebo | 96.4 | percentage of participants event-free | ||
| Percentage of Patients Free From Contralateral Breast Cancer | Group 1: Tamoxifen + Anastrozole Placebo | 94.7 | percentage of participants event-free | ||
| Percentage of Patients Free From Contralateral Breast Cancer | Group 2: Anastrozole + Tamoxifen Placebo | 97.0 | percentage of participants event-free | ||
| Percentage of Patients Free From Non-breast Secondary Cancer | Group 1: Tamoxifen + Anastrozole Placebo | 91.5 | percentage of participants event-free | ||
| Percentage of Patients Free From Non-breast Secondary Cancer | Group 2: Anastrozole + Tamoxifen Placebo | 91.9 | percentage of participants event-free | ||
| Percentage of Patients Free From Osteoporotic Fractures | Group 1: Tamoxifen + Anastrozole Placebo | 96.0 | percentage of participants event-free | ||
| Percentage of Patients Free From Osteoporotic Fractures | Group 2: Anastrozole + Tamoxifen Placebo | 95.3 | percentage of participants event-free | ||
| Percentage of Patients Alive and Disease-free | Group 1: Tamoxifen + Anastrozole Placebo | 77.9 | percentage of participants event-free | ||
| Percentage of Patients Alive and Disease-free | Group 2: Anastrozole + Tamoxifen Placebo | 82.7 | percentage of participants event-free | ||
| Percentage of Patients Alive (Overall Survival) | Group 1: Tamoxifen + Anastrozole Placebo | 92.1 | percentage of participants event-free | ||
| Percentage of Patients Alive (Overall Survival) | Group 2: Anastrozole + Tamoxifen Placebo | 92.5 | percentage of participants event-free | ||
| Quality of Life-Short Form 12 (SF-12) Physical Health Component Score | Group 1: Tamoxifen + Anastrozole Placebo | 46.20 | Standard Deviation 10.13 | units on a scale | |
| Quality of Life-Short Form 12 (SF-12) Physical Health Component Score | Group 2: Anastrozole + Tamoxifen Placebo | 45.38 | Standard Deviation 10.25 | units on a scale | |
| Quality-adjusted Survival Time | Group 1: Tamoxifen + Anastrozole Placebo | 104.4 | 95% Confidence Interval 101.8 to 106.9 | months | |
| Quality-adjusted Survival Time | Group 2: Anastrozole + Tamoxifen Placebo | 102.9 | 95% Confidence Interval 100.9 to 104.9 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00053898/results